ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Chrónos and Káiros in theragnostics: re-assessing time toxicity in final-line radiopharmaceutical treatments.European journal of nuclear medicine and molecular imaging · 2026Article
- Molecular glue degraders: Rational design, specificity engineering, and advanced delivery.Acta pharmaceutica Sinica. B · 2026Review
- High folate receptor expression is associated with aggressive features in prostate cancer with low prostate-specific membrane antigen expression.BJUI compass · 2026Article
- Integrating Multiparametric MRI and PSMA PET Imaging in Prostate Cancer: Toward a Unified Diagnostic and Risk-Stratification Paradigm.Medicina (Kaunas, Lithuania) · 2026Review
- [European journal of nuclear medicine and molecular imaging · 2026Article
- PSMA-RADS 2.0: a revised framework for PSMA-targeted imaging interpretation and clinical decision-making.Abdominal radiology (New York) · 2026Review
- Molecular targets and the emerging role of copper radionuclides in prostate cancer theranostics.EJNMMI research · 2025Review
- Theranostics in nuclear medicine: the era of precision oncology.Medical oncology (Northwood, London, England) · 2025Review
- A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer.NPJ precision oncology · 2025Article
- Article
- Special Issue "In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research".Pharmaceuticals (Basel, Switzerland) · 2023Article
- The VISION Forward: Recognition and Implication of PSMA-/Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.Frontiers in cell and developmental biology · 2022Review
- Radiolabeled PSMA Inhibitors.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.